Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Pliant Therapeutics (PLRX) Receivables - Net (2019 - 2023)

Pliant Therapeutics (PLRX) has disclosed Receivables - Net for 5 consecutive years, with $1.6 million as the latest value for Q2 2023.

  • On a quarterly basis, Receivables - Net fell 68.33% to $1.6 million in Q2 2023 year-over-year; TTM through Jun 2023 was $1.6 million, a 68.33% decrease, with the full-year FY2022 number at $2.0 million, down 0.75% from a year prior.
  • Receivables - Net was $1.6 million for Q2 2023 at Pliant Therapeutics, down from $3.3 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $9.3 million in Q4 2020 to a low of $1.2 million in Q1 2022.
  • A 5-year average of $3.5 million and a median of $2.1 million in 2021 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: crashed 78.47% in 2021, then surged 172.62% in 2022.
  • Pliant Therapeutics' Receivables - Net stood at $7.1 million in 2019, then surged by 31.58% to $9.3 million in 2020, then plummeted by 78.47% to $2.0 million in 2021, then fell by 0.75% to $2.0 million in 2022, then decreased by 20.32% to $1.6 million in 2023.
  • Per Business Quant, the three most recent readings for PLRX's Receivables - Net are $1.6 million (Q2 2023), $3.3 million (Q1 2023), and $2.0 million (Q4 2022).